ArticleClinical and experimental hepatology2024
Treatment of HCV infection in patients with steatotic liver disease.
Article in Clinical and experimental hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Precise delivery of medical gases by engineered nanomedicine for enhanced liver fibrosis therapy.Materials today. Bio · 2026Review
- Steatotic liver disease in patients with chronic hepatitis C.World journal of hepatology · 2025Article
- Present and Future Perspectives in the Treatment of Liver Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Steatotic liver disease and chronic viral hepatitis.Clinical and experimental hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: The aim of the study was to characterize the population with hepatitis C virus (HCV) infection and steatotic liver disease (SLD) in comparison to the non-SLD HCV-infected patients and to evaluate the effectiveness of treatment with direct-acting antivirals (DAA). Material and methods: The analysis included 62 patients diagnosed with SLD and 14,284 non-SLD patients from the EpiTer-2 database for the period 2015-2022. Results: Unlike the non-SLD population, the SLD group was dominated by men (49.5% vs. 53.2%, respectively). The mean age of patients did not differ significantly between groups and was 50.8 ±13.8 and 50.8 ±14.9 years for SLD and non-SLD, respectively. As expected, patients with SLD had significantly different BMI values. Genotype (GT) 1b infection predominated in both populations, but the prevalence of GT3 was significantly higher in the SLD group (19.4% vs. 10.6%). The percentage of patients with advanced liver disease (F3/4) was similar in both groups (38.7% vs. 35.6%). Patients with SLD were more likely to be treatment naïve (82.3% vs. 80.5%), HBV co-infected (24.2% vs. 13.6%), and obese (54.8% vs. 17.1%). Out of 62 patients, 59 (95%) achieved a sustained virologic response (SVR), but after excluding 3 lost to follow-up a response rate of 100% was obtained. The corresponding SVR values in the non-SLD HCV-infected population were 95% and 98%, respectively. Conclusions: Despite some differences in the characteristics of patients with SLD infected with HCV, the effec-tiveness of DAA therapy does not differ significantly from that observed in the general population infected with HCV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.